A Las Vegas-based cannabinoid company is putting down Ottawa roots in the hope of capitalizing on Canada’s less restrictive cannabis market.
GB Sciences announced Tuesday it is establishing its first non-U.S. footprint, dubbed GBS Global Biopharma, in Ottawa.
A release states that the company’s Canadian entity will research and develop cannabinoid-based medicines with the help of Canada’s legal market, tax credits and favourable exchange rates.
OBJ360 (Sponsored)

Ottawa Jazz Festival’s location is key to its success – and to revitalizing the downtown core
This year marks the 45th anniversary of the Ottawa Jazz Festival, one of the city’s premier live music events and Canada’s second oldest jazz festival. Despite the ever-changing (and expanding)

Nicole Arranz lights up whenever she sees or hears children visiting Perley Health’s east-end Ottawa campus. “My mom loves kids, and being around kids brings life to her,” said Josée
Regulatory frameworks north of the border will also foster international collaboration, GB Sciences said. The company’s researchers work with partners in the United States, Spain and Greece on prescription drug programs, cannabinoid delivery technology and nutraceuticals, more commonly known as supplements.
“Canada’s policies will allow GBS Global to bring our next-generation cannabinoid medications to market quickly, safely and legally. Canada’s regulations, in particular, mean treatments can be evaluated and approved in less time than it would take in the U.S.,” said GB Sciences CEO John Poss in a statement.